Safety of Drug-Induced Renal Acid-Base Disturbances: A Comprehensive Clinical Review

Abstract

Drug-induced renal acid-base disturbances represent a significant clinical concern due to their prevalence, potential for morbidity, and impact on patient outcomes. Various pharmacologic agents can disrupt renal acid-base homeostasis, leading to metabolic acidosis or alkalosis, with complex underlying mechanisms. This review synthesizes current evidence from clinical research and guidelines to provide an in-depth analysis of epidemiology, pathophysiology, risk factors, clinical features, diagnostic strategies, management options, and recent therapeutic advances. The aim is to equip clinicians with practical, mechanism-based insights for optimal patient care in the context of drug-induced acid-base disorders.

Introduction

Renal acid-base disturbances induced by pharmacological agents are increasingly recognized in clinical practice, particularly among patients with polypharmacy or underlying renal disease. These disturbances can present as either metabolic acidosis or alkalosis and may lead to significant complications if not promptly identified and managed. Understanding the causative drugs, underlying pathophysiological mechanisms, and clinical manifestations is crucial for timely diagnosis and effective intervention. This article aims to provide a scientific overview of the safety of drug-induced renal acid-base disturbances, emphasizing evidence-based strategies for detection, prevention, and management.

Epidemiology / Disease Burden

The incidence of drug-induced renal acid-base disturbances is difficult to estimate precisely due to underreporting and diagnostic challenges. However, studies suggest that up to 10% of hospitalized patients may experience drug-related metabolic derangements, particularly those receiving diuretics, carbonic anhydrase inhibitors, or nephrotoxic antibiotics. The burden is higher in the elderly, patients with chronic kidney disease (CKD), and those with complex medication regimens. The disease burden is underscored by the potential progression to acute kidney injury, hospitalization, and increased mortality if unrecognized.

Pathophysiology

Drug-induced acid-base disturbances arise from interference with renal tubular function, bicarbonate reclamation, hydrogen ion secretion, or electrolyte handling. Diuretics such as thiazides and loop agents can induce metabolic alkalosis by promoting sodium and chloride loss, volume contraction, and increased distal sodium delivery leading to enhanced hydrogen and potassium excretion. Conversely, drugs like carbonic anhydrase inhibitors (e.g., acetazolamide) and certain antimicrobials impair bicarbonate reabsorption, resulting in proximal renal tubular acidosis. Other agents, such as amphotericin B, disrupt distal tubular membrane integrity, leading to distal renal tubular acidosis. Renin-angiotensin-aldosterone system inhibitors may precipitate hyperkalemic metabolic acidosis by diminishing aldosterone-mediated hydrogen and potassium excretion.

Risk Factors

Several risk factors predispose patients to drug-induced renal acid-base disturbances. These include advanced age, pre-existing renal impairment, heart failure, liver disease, diabetes mellitus, and concomitant use of multiple nephrotoxic or electrolyte-altering medications. Genetic polymorphisms affecting drug metabolism or renal tubular transporters may also increase susceptibility. Clinical vigilance is warranted in populations with high baseline risk, particularly when initiating or titrating drugs known to affect renal acid-base physiology.

Clinical Features

The clinical presentation of drug-induced renal acid-base disturbances is often nonspecific and may overlap with underlying comorbidities. Common manifestations include malaise, fatigue, confusion, dyspnea, nausea, and muscle weakness. Severe disturbances can precipitate arrhythmias, seizures, or progression to acute kidney injury. Laboratory findings are pivotal and may demonstrate altered serum bicarbonate, pH, potassium, chloride, and anion gap. Clinical context, medication history, and temporal association with drug exposure are essential for accurate diagnosis.

Diagnosis

Diagnosis requires a systematic approach integrating clinical assessment, laboratory evaluation, and review of current medications. Arterial blood gas analysis, serum electrolytes, and calculation of the anion and osmolal gaps guide differentiation between metabolic acidosis and alkalosis and help identify mixed disorders. Urinary pH and electrolyte measurements provide insight into renal tubular function. Medication reconciliation and temporal correlation with symptom onset are critical. In some cases, genetic testing or renal biopsy may be indicated to exclude underlying renal pathology.

Treatment & Management

Management centers on prompt identification and discontinuation or dose adjustment of the offending agent. Supportive care includes correction of electrolyte and fluid imbalances, acid-base status, and, if necessary, renal replacement therapy in severe cases. Alkali supplementation (e.g., sodium bicarbonate) may be indicated for persistent metabolic acidosis, while potassium repletion and volume expansion address metabolic alkalosis. Close monitoring of renal function, electrolytes, and acid-base parameters is essential during therapy. Patient education and periodic medication review help prevent recurrence.

Recent Advances / Emerging Therapies

Recent advances focus on pharmacogenetic risk profiling to predict susceptibility to drug-induced renal tubular dysfunction. Novel biomarkers, such as urinary NGAL and kidney injury molecule-1 (KIM-1), are under investigation for early detection of tubular injury before overt acid-base derangement. Therapeutic approaches targeting specific transporters or modulating drug pharmacokinetics are in development. Integration of electronic health record alerts for high-risk medications shows promise in reducing incidence through real-time clinical decision support.

Guideline Recommendations

Current nephrology and clinical pharmacology guidelines emphasize the importance of medication reconciliation, individualized risk assessment, and proactive monitoring in patients at risk for drug-induced renal acid-base disturbances. Recommendations include baseline and periodic laboratory monitoring, especially after drug initiation or dose escalation. Guidelines advocate for the lowest effective dose and duration of therapy, avoidance of polypharmacy where possible, and patient education on early symptom recognition. Collaborative care involving pharmacists, nephrologists, and primary providers is endorsed to optimize outcomes.

Conclusion

Drug-induced renal acid-base disturbances constitute a significant yet preventable cause of morbidity in clinical practice. Awareness of the epidemiology, pathophysiology, risk factors, and clinical features enables timely identification and intervention. Mechanism-based management strategies, informed by current guidelines and emerging evidence, are essential to ensure patient safety. Ongoing research into predictive biomarkers and personalized therapeutics may further enhance prevention and management in the future.